Iridescent
发表于 2025-3-21 18:54:16
书目名称Gastrointestinal Stromal Tumor影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0380887<br><br> <br><br>书目名称Gastrointestinal Stromal Tumor影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0380887<br><br> <br><br>书目名称Gastrointestinal Stromal Tumor网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0380887<br><br> <br><br>书目名称Gastrointestinal Stromal Tumor网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0380887<br><br> <br><br>书目名称Gastrointestinal Stromal Tumor被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0380887<br><br> <br><br>书目名称Gastrointestinal Stromal Tumor被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0380887<br><br> <br><br>书目名称Gastrointestinal Stromal Tumor年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0380887<br><br> <br><br>书目名称Gastrointestinal Stromal Tumor年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0380887<br><br> <br><br>书目名称Gastrointestinal Stromal Tumor读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0380887<br><br> <br><br>书目名称Gastrointestinal Stromal Tumor读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0380887<br><br> <br><br>
Antarctic
发表于 2025-3-21 23:39:21
http://reply.papertrans.cn/39/3809/380887/380887_2.png
凌辱
发表于 2025-3-22 03:09:04
Book 2019oplasms arising within the gastrointestinal tract. The causative gene of this disease was originally discovered in Japan by Prof. Seichi Hirota in 1998, and since then numerous important advances – from basic to clinical aspects – have been reported from Japan. Professionals involved in the manageme
窝转脊椎动物
发表于 2025-3-22 05:58:38
https://doi.org/10.1007/978-3-662-00599-6red as at least some malignancy (labeled as /1 or /3 in the behavior code of ICD-O-3). We do not know how many cases are there that are considered as benign. Some summaries of the current status of GIST treatment are provided using the same dataset.
偶然
发表于 2025-3-22 09:24:19
,Modellrechnung zur Chemie der Atmosphäre,n is recommended for imatinib-resistant GISTs. Regorafenib should be considered in patients with imatinib or sunitinib-resistant GISTs. During these tyrosine kinase therapies, surgery should be considered if feasible.
Grasping
发表于 2025-3-22 16:38:48
Epidemiology,red as at least some malignancy (labeled as /1 or /3 in the behavior code of ICD-O-3). We do not know how many cases are there that are considered as benign. Some summaries of the current status of GIST treatment are provided using the same dataset.
Grasping
发表于 2025-3-22 18:51:50
Treatment Guidelines,n is recommended for imatinib-resistant GISTs. Regorafenib should be considered in patients with imatinib or sunitinib-resistant GISTs. During these tyrosine kinase therapies, surgery should be considered if feasible.
decode
发表于 2025-3-22 22:25:58
http://reply.papertrans.cn/39/3809/380887/380887_8.png
痛打
发表于 2025-3-23 03:56:24
First-Line Treatment,ct of imatinib is the trough level of imatinib. Although the treatment results improved, primary resistant cases, in which the effect of imatinib cannot be expected from the beginning, and secondary resistant cases, in which the effect was exhibited at the beginning but resistance was exhibited later, have become problematic.
无法治愈
发表于 2025-3-23 09:03:19
http://reply.papertrans.cn/39/3809/380887/380887_10.png